Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas

Neuro-Oncology

Volumn 14, Issue 4, 2012, Pages 496-505

  Pallud, Johan ^a,b,f   Llitjos, Jean François ^a,b   Dhermain, Frédéric ^c   Varlet, Pascale ^a,b   Dezamis, Edouard ^a,b   Devaux, Bertrand ^a,b   Souillard Scémama, Raphaëlle ^a,b   Sanai, Nader ^e   Koziak, Maria ^a,b   Page, Philippe ^a,b   Schlienger, Michel ^d   Daumas Duport, Catherine ^b   Meder, Jean François ^a,b   Oppenheim, Catherine ^a,b   Roux, François Xavier ^a,b  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d HÔPITAL TENON   (France)

^e BARROW NEUROLOGICAL INSTITUTE   (United States)

^f Réseau d'Etude des Gliomes REG   (France)

Author keywords

growth rates; low grade glioma; prognosis; radiation therapy

Indexed keywords

FOTEMUSTINE; ISOCITRATE DEHYDROGENASE; PROTEIN P53; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DIFFUSE LOW GRADE GLIOMA; FEMALE; FOLLOW UP; GLIOMA; HUMAN; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; RADIOLOGICAL PARAMETERS; TREATMENT RESPONSE; TUMOR VOLUME; VELOCITY OF DIAMETRIC EXPANSION;

ADULT; AGED; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84859529487     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos069     Document Type: Article

References (29)

1. Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010;17:1124-1133.
2. Duffau H. Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity. Lancet Neurol. 2005;4:476-486. (Pubitemid 40982458)
3. Wessels PH, Weber WE, Raven G, et al. Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol. 2003; 2:395-403. (Pubitemid 36793931)
4. Sanai N, Mirzadeh Z, Berger MS. Functional outcome after language mapping for glioma resection. N Engl J Med. 2008;358:18-27.
5. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62:753-764.
6. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985-990. (Pubitemid 41323034)
7. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002;20:2267-2276. (Pubitemid 34441653)
8. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36: 549-556. (Pubitemid 26404297)
9. van den Bent M, Wefel J, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011; 12:583-593.
10. Mandonnet E, Pallud J, Clatz O, et al. Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm. Neurosurg Rev. 2008;31:263-269.
11. Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53:524-528. (Pubitemid 36373265)
12. Pallud J, Mandonnet E, Duffau H, et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol. 2006;60:380-383. (Pubitemid 44520241)
13. Mandonnet E, Pallud J, Fontaine D, et al. Inter-and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurg Rev. 2010;33:91-96.
14. Peyre M, Cartalat-Carel S, Meyronet D, et al. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol. 2010;12: 1078-1082.
15. Ricard D, Kaloshi G, Amiel-Benouaich A, et al. Dynamic history of lowgrade gliomas before and after temozolomide treatment. Ann Neurol. 2007;61:484-490. (Pubitemid 46878776)
16. Pallud J, Duffau H, Razak RA, et al. Influence of pregnancy in the behavior of diffuse gliomas: clinical cases of a French glioma study group. J Neurol. 2009;256:2014-2020.
17. Reifenberger G, Kros JM, Louis DN, et al. Oligodendroglioma. In: Louis, DN, Ohgaki, H, Wiestler, OD, et al., eds. WHO Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer (IARC); 2007:54-59.
18. von Deimling A, Burger PC, Nakazato Y, et al. Diffuse astrocytomas. In: Louis, DN, Ohgaki, H, Wiestler, OD, et al., eds. WHO Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer (IARC); 2007:25-29.
19. Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro Oncol. 2009;11:176-182.
20. Daumas-Duport C, Beuvon F, Varlet P, et al. [Gliomas: WHO and Sainte-Anne Hospital classifications]. Ann Pathol. 2000;20:413-428.
21. Daumas-Duport C, Tucker ML, Kolles H, et al. Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. J Neurooncol. 1997;34:61-78. (Pubitemid 27270252)
22. Daumas-Duport C, Varlet P, Tucker ML, et al. Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol. 1997;34:37-59. (Pubitemid 27270251)
23. Pallud J, Varlet P, Devaux B, et al. Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities. Neurology. 2010; 74:1724-1731.
24. Capper D, Reuss D, Schittenhelm J, et al. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol. 2011;121:241-252.
25. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20:245-254.
26. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076-2084. (Pubitemid 34408798)
27. Wen PY, Norden AD, Drappatz J, et al. Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep. 2010;12:68-75.
28. Bauman G, Pahapill P, MacDonald D, et al. Low grade glioma: a measuring radiographic response to radiotherapy. Can J Neurol Sci. 1999;26:18-22. (Pubitemid 29088319)
29. Fisher BJ, Bauman GS, Leighton CE, et al. Low-grade gliomas in children: tumor volume response to radiation. J Neurosurg. 1998;88:969-974. (Pubitemid 28261842)